Erasca rallied by 8.94 percent on Tuesday to close at $19.50 apiece, as investor sentiment was boosted by the strong clinical trial results of its treatment candidate for RAS-mutant solid tumors, strengthening investor confidence that the drug could become a potential treatment option for difficult-to-treat RAS-mutant cancers.
Based on data from the phase 1 clinical trial, Erasca Inc.’s (NASDAQ:ERAS) treatment candidate—ERAS-0015—showed strong results, successfully shrinking tumors of patients with pancreatic cancer by 57 percent after eight weeks. The encouraging response is notable because pancreatic cancer remains one of the deadliest cancers, with few effective treatment options, making positive early-stage data closely watched by investors.
For illustration purposes only. Photo by Tima Miroshnichenko on Pexels
Of the seven enrolled patients, most remained on treatment, suggesting a continued favorable safety profile for the drug.
ERAS-0015 also reported encouraging early results when combined with panitumumab, an approved colorectal cancer drug. Additional data from the combined therapy is targeted for release in the first half of 2027.
Erasca Inc. (NASDAQ:ERAS) is planning to initiate a clinical trial for ERAS-0015 to test its efficacy in lung cancer patients in the first half of 2027 and advance the study into phase 3 in the second half or in the first half of 2028.
It is also targeting a phase 3 trial in pancreatic cancer next year.
14% Price Target Hike
Following the results, investment firm Jefferies raised its price target for the company by 14 percent to $24 from $21 previously, marking a 23 percent upside potential from its latest closing price.
Jefferies also reiterated its “buy” recommendation for Erasca Inc. (NASDAQ:ERAS), saying that the stock is currently underappreciated and that its value still does not reflect ERAS-0015’s efficacy and, potentially, cleaner safety profile versus daraxonrasib—an investigational drug being developed by Revolution Medicines.
Apart from Jefferies, Erasca Inc. (NASDAQ:ERAS) also maintained a buy recommendation and a $20 price target from HC Wainwright.
Rising Hedge Fund Interest
Institutional investors also appear to be warming up to Erasca Inc. (NASDAQ:ERAS).
Based on Insider Monkey’s data for the first quarter of the year, a total of 51 hedge funds out of 1,022 held positions in the company, markedly higher than the 32 hedge funds in the quarter prior.
The increase strongly suggests that they are positioning ahead of key clinical milestones.
$550-Million Share Sale
In line with the study, Erasca Inc. (NASDAQ:ERAS) launched a new follow-on offering (FOO) in a bid to raise as much as $632 million in fresh funds.
Under the offer, it will offer more than 31.4 million new common shares at a price of $17.50 apiece, with an additional overallotment option of 4.7 million shares at the offering price for 30 days.
The offer is expected to close tomorrow, July 15, subject to customary closing conditions.
Erasca Inc. (NASDAQ:ERAS) said that it intends to use the net proceeds from the offer, together with its existing cash, cash equivalents and marketable securities, to fund the research and development of its product candidates and other development programs.
Meanwhile, the balance will be allocated for working capital and other general corporate purposes.
While we acknowledge the risk and potential of ERAS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ERAS and that has 10,000% upside potential, check out our report about thecheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
